BioInvent International AB
STO:BINV
BioInvent International AB
Revenue
BioInvent International AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
BioInvent International AB
STO:BINV
|
Revenue
kr44.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-1%
|
|
![]() |
Biogaia AB
STO:BIOG B
|
Revenue
kr1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
![]() |
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr997.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
![]() |
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
![]() |
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr26B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
![]() |
BioArctic AB
STO:BIOA B
|
Revenue
kr257.4m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
What is BioInvent International AB's Revenue?
Revenue
44.7m
SEK
Based on the financial report for Dec 31, 2024, BioInvent International AB's Revenue amounts to 44.7m SEK.
What is BioInvent International AB's Revenue growth rate?
Revenue CAGR 10Y
-1%
Over the last year, the Revenue growth was -37%. The average annual Revenue growth rates for BioInvent International AB have been 32% over the past three years , -14% over the past five years , and -1% over the past ten years .